|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
6
|
|
gptkbp:bfsParent
|
gptkb:Ranitidine
|
|
gptkbp:activities
|
H2 receptor antagonist
|
|
gptkbp:approves
|
gptkb:legislation
gptkb:1986
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:brand
|
gptkb:Pepcid
|
|
gptkbp:category
|
B
|
|
gptkbp:clinical_trial
|
Phase IV
Phase III
40% to 50%
|
|
gptkbp:contraindication
|
severe renal impairment
hypersensitivity to famotidine
|
|
gptkbp:discovered_by
|
gptkb:Merck_&_Co.
|
|
gptkbp:dosage_form
|
once or twice daily
20 mg to 40 mg
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
gptkb:tablet
suspension
injection
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Famotidine
|
|
gptkbp:ingredients
|
C8 H10 N4 O2 S
|
|
gptkbp:interacts_with
|
may interact with antacids
may interact with ketoconazole
may interact with warfarin
|
|
gptkbp:is_atype_of
|
A02 B A03
|
|
gptkbp:is_available_on
|
generic drug
|
|
gptkbp:is_used_for
|
treating gastroesophageal reflux disease (GERD)
treating peptic ulcers
preventing stomach ulcers
|
|
gptkbp:lifespan
|
2.5 to 3.5 hours
|
|
gptkbp:manager
|
oral
intravenous
|
|
gptkbp:marketed_as
|
gptkb:Pepcid_AC
gptkb:Pepcid_Complete
gptkb:Pepcid_Oral_Suspension
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:rounds
|
renal
|
|
gptkbp:side_effect
|
dizziness
headache
nausea
diarrhea
constipation
arrhythmias
thrombocytopenia
hepatotoxicity
gynecomastia
confusion in elderly patients
|
|
gptkbp:storage
|
store at room temperature
protect from moisture
|
|
gptkbp:type_of
|
76824-35-6
|
|
gptkbp:year_created
|
1970s
|